Future predctions, page-8

A major elephant in the room before last week was how are CGL going to materialize partnerships with 'Canntab' & 'Pharmocann'?

One of the questions I had put to Sholom in December was basically how was CGL going to move to manufacturing?

This critical question has now been answered with the latest BioHealth deal. Saves the company millions of dollars in equipment & gives us an almost immediate capacity to start manufacturing products.

Will be interesting how this latest developement is able to translate to revenue in the short term? I really had not anticipated CGL having this capability so soon.

Should the manufacturing at BioHealth & expansion of CGL into Australian/Asian markets go well than there is so much to like about this company. Even if the uptake of medicinal marijuana products is slow to start over the next few years I'm sure the consumables & skin care products will hold CGL in good stead.

If we have favourable harvest news in March/April than this stock could get very interesting on re-lisitng!

Revenue has always been the bench mark. Regardless of whether this stock is trading on these developments or not cream always rises to the top! A mature business plan that leads to demonstrated revenue will certainly propel the share price forward with a new found support levels.